The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | Considerations when selecting a pharmacological pain management strategy in SCD or thalassemia
Rana Yamout, MD, American University of Beirut Medical Center, Beirut, Lebanon, outlines some of the key considerations for clinicians when deciding which pharmacological pain management strategy they should utilize for a patient with sickle cell disease (SCD) or thalassemia. Dr Yamout highlights that the availability and accessibility of an agent, the type of pain, and the severity of pain should all be considered. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So usually, when the physician would like to prescribe any medication, we should take into consideration the availability of medication, its accessibility, and also the type of pain that the patient is dealing with and the severity of pain. For instance, if the patient is in severe pain, so as per the WHO ladder, we have to prescribe strong opioids. But again, it depends on the availability and accessibility of medication because most of the medications are not usually reimbursed or covered by third party payer...
So usually, when the physician would like to prescribe any medication, we should take into consideration the availability of medication, its accessibility, and also the type of pain that the patient is dealing with and the severity of pain. For instance, if the patient is in severe pain, so as per the WHO ladder, we have to prescribe strong opioids. But again, it depends on the availability and accessibility of medication because most of the medications are not usually reimbursed or covered by third party payer. So we have to take into consideration how much every patient can afford the medication or not. So it depends, just to summarize, to make it clear, it depends on the availability, accessibility of medication, the type of pain the patient is dealing with, whether it is nociceptive or neuropathic pain, and the severity of pain.
Read more...
